title: γδ T cells and epigenetic drugs: A useful merger in cancer immunotherapy?
abstract: γδ T cell-based immunotherapeutic strategies in cancer patients are as yet of limited success. Drugs targeting epigenetic mechanisms including histone acetylation and DNA methylation trigger cell death in tumor cells but in addition have immunomodulatory activity. Here, we discuss the potential benefit of combining both strategies in cancer immunotherapy.
authors.affiliation: Institute of Immunology; University of Kiel and UKSH Campus Kiel ; Kiel, Germany.
authors.forename: Jaydeep
authors.initials: J
authors.lastname: Bhat
authors.affiliation: Institute of Immunology; University of Kiel and UKSH Campus Kiel ; Kiel, Germany.
authors.forename: Dieter
authors.initials: D
authors.lastname: Kabelitz
keywords: DNMTi, DNA methyltransferase inhibitor(s); HDACi, histone deacetylase inhibitor(s); IL-2, interleukin-2; N-BP, nitrogen-containing bisphosphonate; NKG2D, natural killer group 2 member D; NSCLC, non-small cell lung cancer; epigenetic drugs; histone deacetylase inhibitor; immunotherapy; tumor cell; γδ T cells